Akinsanya Karen sold Schrodinger Inc. ($SDGR) shares on the open market five times over the past year, totaling about $464 thousand, with her most recent sale on March 5, 2026. Her sales rank 6,626th among 11,678 individual insiders, below the average of $8.6 million per seller and 6.4 transactions. She made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 5, 2026 | Schrodinger, Inc. | $SDGR | Akinsanya Karen | See Remarks | S | Common Stock | 1366 | $12.90 | 69,956.0000 | 73,613,090 | 1.92% | 0.00% |
| March 2, 2026 | Schrodinger, Inc. | $SDGR | Akinsanya Karen | See Remarks | A | Common Stock | 24250 | $0.00 | 39,875.0000 | 73,613,090 | 155.20% | 0.03% |
| March 2, 2026 | Schrodinger, Inc. | $SDGR | Akinsanya Karen | See Remarks | A | Stock Option (right to buy) | 48500 | $0.00 | 48,500.0000 | 73,613,090 | 9999.99% | 0.07% |
| March 2, 2026 | Schrodinger, Inc. | $SDGR | Akinsanya Karen | See Remarks | S | Common Stock | 2206 | $11.99 | 71,322.0000 | 73,613,090 | 3.00% | 0.00% |
| March 2, 2026 | Schrodinger, Inc. | $SDGR | Akinsanya Karen | See Remarks | A | Common Stock | 27576 | $0.00 | 73,528.0000 | 73,613,090 | 60.01% | 0.04% |
| March 2, 2026 | Schrodinger, Inc. | $SDGR | Akinsanya Karen | See Remarks | A | Common Stock | 6077 | $0.00 | 45,952.0000 | 73,613,090 | 15.24% | 0.01% |
| June 23, 2025 | Nautilus Biotechnology, Inc. | $NAUT | Akinsanya Karen | Director | A | Stock Option (Right to Buy) | 45000 | $0.00 | 45,000.0000 | 126,148,469 | 9999.99% | 0.04% |
| April 14, 2025 | Schrodinger, Inc. | $SDGR | Akinsanya Karen | President of R&D, Therapeutics | M | Stock Option (right to buy) | 3345 | $0.00 | 0.0000 | 72,670,295 | 100.00% | 0.00% |
| April 14, 2025 | Schrodinger, Inc. | $SDGR | Akinsanya Karen | President of R&D, Therapeutics | M | Stock Option (right to buy) | 13378 | $0.00 | 0.0000 | 72,670,295 | 100.00% | 0.02% |
| April 14, 2025 | Schrodinger, Inc. | $SDGR | Akinsanya Karen | President of R&D, Therapeutics | M | Common Stock | 3345 | $2.92 | 32,348.0000 | 72,670,295 | 11.53% | 0.00% |
| April 14, 2025 | Schrodinger, Inc. | $SDGR | Akinsanya Karen | President of R&D, Therapeutics | M | Common Stock | 13378 | $3.22 | 29,003.0000 | 72,670,295 | 85.62% | 0.02% |
| April 14, 2025 | Schrodinger, Inc. | $SDGR | Akinsanya Karen | President of R&D, Therapeutics | S | Common Stock | 8378 | $25.11 | 23,970.0000 | 72,670,295 | 25.90% | 0.01% |
| April 14, 2025 | Schrodinger, Inc. | $SDGR | Akinsanya Karen | President of R&D, Therapeutics | S | Common Stock | 5000 | $25.11 | 18,970.0000 | 72,670,295 | 20.86% | 0.01% |
| April 14, 2025 | Schrodinger, Inc. | $SDGR | Akinsanya Karen | President of R&D, Therapeutics | S | Common Stock | 3345 | $25.00 | 15,625.0000 | 72,670,295 | 17.63% | 0.00% |
| March 3, 2025 | Schrodinger, Inc. | $SDGR | Akinsanya Karen | President of R&D, Therapeutics | A | Common Stock | 15625 | $0.00 | 15,625.0000 | 72,670,295 | 9999.99% | 0.02% |
| March 3, 2025 | Schrodinger, Inc. | $SDGR | Akinsanya Karen | President of R&D, Therapeutics | A | Stock Option (right to buy) | 62500 | $0.00 | 62,500.0000 | 72,670,295 | 9999.99% | 0.09% |
| June 14, 2024 | Nautilus Biotechnology, Inc. | $NAUT | Akinsanya Karen | Director | A | Stock Option (Right to Buy) | 45000 | $0.00 | 45,000.0000 | 0 | 9999.99% | 0.00% |
| March 4, 2024 | Schrodinger, Inc. | $SDGR | Akinsanya Karen | President of R&D, Therapeutics | A | Stock Option (right to buy) | 120000 | $0.00 | 120,000.0000 | 74,986,816 | 9999.99% | 0.16% |
| June 15, 2023 | Nautilus Biotechnology, Inc. | $NAUT | Akinsanya Karen | Director | A | Stock Option (Right to Buy) | 45000 | $0.00 | 45,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 9, 2023 | Schrodinger, Inc. | $SDGR | Akinsanya Karen | President of R&D, Therapeutics | A | Stock Option (right to buy) | 63270 | $0.00 | 63,270.0000 | 71,173,419 | 9999.99% | 0.09% |